503A generally centres on identified patients and prescriptions; 503B is an outsourcing-facility pathway that can accommodate non-patient-specific supply when its conditions are met. Neither designation independently makes a particular GLP-1 preparation eligible. (fda.gov)
| Issue | Section 503A | Section 503B |
|---|---|---|
| Typical operator | Licensed pharmacist in a qualifying pharmacy or licensed physician | Registered outsourcing facility |
| Patient-specific prescription | Generally required, with limited anticipatory compounding provisions | Not necessarily required |
| Manufacturing framework | Qualifying drugs receive specified exemptions, including from CGMP | CGMP obligations remain |
| Copying restrictions | Restrictions on regularly or inordinately compounding essentially copies | Separate restrictions on essentially copies of approved drugs |
| Bulk ingredients | Must satisfy 503A ingredient conditions | Must satisfy separate 503B bulk-substance conditions |
These distinctions come from FDA’s statutory comparison and outsourcing-facility materials. (fda.gov)
Buyer action: identify the actual producing facility and pathway for each preparation. A corporate group with both pharmacy and outsourcing operations should not be evaluated as one undifferentiated supplier.
Explore the table row by row
A working view of the research
Typical operator
- Section 503A
- Licensed pharmacist in a qualifying pharmacy or licensed physician
- Section 503B
- Registered outsourcing facility
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding